Our Take
Real-world evidence studies are standard regulatory scaffolding, not product validation; this is early-stage data collection that will take months to yield clinically actionable results.
Why it matters
Pharma companies increasingly rely on real-world evidence to support market access and payer negotiations in Europe. For Pepaxti specifically, the study aims to bridge the gap between trial data and how the drug actually performs in everyday clinical settings, particularly in combination with newer immunotherapies.
Do this week
Oncology medical affairs teams: flag this study's expected data maturity timeline (likely 2027–2028) when planning European health authority submissions or HTA dossiers.
First patient enrolled in German real-world evidence trial
Oncopeptides has enrolled its first patient into Marina, a real-world evidence study running across approximately 25 clinical sites in Germany. The trial will follow 50 patients with relapsed, refractory multiple myeloma who have received at least three prior lines of therapy (company-reported). iOMEDICO serves as the study sponsor and coordinator; Oncopeptides provides financial backing.
The study will measure Disease Control Rate and evaluate Pepaxti's role as a bridging or sequencing option alongside CAR-T cells and bispecific antibodies. Enrollment began in the second quarter of 2026, in line with the company's prior guidance. Recruitment is supported by the SYNERGY platform, which activates clinical centres "just-in-time" once eligible patients are identified.
Real-world data closes a gap; it does not replace phase trials
Real-world evidence studies serve a specific regulatory and commercial purpose: they capture how a drug performs outside the constraints of randomized trials (stricter eligibility, closer monitoring, protocol-driven dosing). European payers and health authorities increasingly expect this data to support coverage and reimbursement decisions. For Pepaxti, the Marina study is designed to document outcomes in everyday practice and inform engagement with European prescribers and regulators.
The key limitation is timing. A 50-patient observational study typically requires 18–24 months to accrue and analyze data. Results will not inform near-term market access; they support longer-term reimbursement negotiations and prescriber confidence. This is routine post-approval surveillance, not a claim that efficacy or safety has been re-validated.
Audit your Pepaxti payer dossiers for 2027 updates
Oncology health economics and market access teams should note Marina's expected data maturity window (likely late 2027 or 2028) and flag it in payer communication plans. Real-world evidence from German sites will carry weight in HTA submissions and pricing discussions across Europe. Monitor iOMEDICO publications and Oncopeptides investor communications for preliminary results and their framing before external presentations.